Zedsen

Zedsen is developing a novel breast cancer screening device, the Z-Scanner, based on Electrical Capacitance Tomography (ECT) and advanced AI/ML algorithms. The technology is designed to be non-invasive, radiation-free, portable, and affordable, targeting improved detection in dense breast tissue and enabling use in primary care clinics. The company is pre-revenue and in the development stage, with a team focused on engineering and data science, aiming to decentralize and democratize early breast cancer detection.

Proprietary adaptation of Electrical Capacitance Tomography (ECT) using a patented flat-sensor electrode array to measure tissue permittivity, combined with bespoke AI/ML algorithms for image reconstruction and cancer risk assessment.

Zedsen competes in the breast imaging market against incumbent mammography systems (Hologic, GE, Siemens), which are improving with tomosynthesis and AI analysis. It also faces competition from other adjunct modalities like ultrasound and MRI, as well as other emerging technologies exploring electrical impedance or other properties for cancer detection.